New York, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Industry" - https://www.reportlinker.com/p06032349/?utm_source=GNW
3 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027. Targeted Therapy, one of the segments analyzed in the report, is projected to record a 10% CAGR and reach US$22.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immunotherapy segment is readjusted to a revised 7.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $6.1 Billion, While China is Forecast to Grow at 13.7% CAGR
The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$6.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.3 Billion by the year 2027 trailing a CAGR of 13.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 7.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.6 Billion by the year 2027.
Chemotherapy Segment to Record 6.8% CAGR
In the global Chemotherapy segment, USA, Canada, Japan, China and Europe will drive the 6.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2 Billion in the year 2020 will reach a projected size of US$3.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 8.2% CAGR through the analysis period.
Select Competitors (Total 34 Featured) -
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genentech Inc.
GlaxoSmithKline plc
Novartis
Pfizer Inc.
Roche Holding AG
Sun Pharmaceutical Industries Ltd.
Read the full report: https://www.reportlinker.com/p06032349/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Key
Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Non-Small Cell Lung Cancer (NSCLC) Therapeutics
Market Analysis of Annual Sales in US$ Million for Years 2012
through 2027
Table 2: World Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 3: World Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 4: World 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2021 & 2027
Table 5: World Recent Past, Current & Future Analysis for
Targeted Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR
Table 6: World Historic Review for Targeted Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 7: World 15-Year Perspective for Targeted Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 8: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 9: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 10: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 11: World Recent Past, Current & Future Analysis for
Chemotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 12: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 13: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 14: World Recent Past, Current & Future Analysis for
Adenocarcinoma by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR
Table 15: World Historic Review for Adenocarcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 16: World 15-Year Perspective for Adenocarcinoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 17: World Recent Past, Current & Future Analysis for
Squamous Cell Carcinoma by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 18: World Historic Review for Squamous Cell Carcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 19: World 15-Year Perspective for Squamous Cell Carcinoma
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 20: World Recent Past, Current & Future Analysis for
Large Cell Carcinoma by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR
Table 21: World Historic Review for Large Cell Carcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 22: World 15-Year Perspective for Large Cell Carcinoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in the United
States for 2022 (E)
Table 23: USA Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 24: USA Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 25: USA 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 26: USA Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 27: USA Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 28: USA 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
CANADA
Table 29: Canada Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 30: Canada Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 31: Canada 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 32: Canada Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 33: Canada Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 34: Canada 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
JAPAN
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Japan for
2022 (E)
Table 35: Japan Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 36: Japan Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 37: Japan 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 38: Japan Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 39: Japan Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 40: Japan 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
CHINA
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in China for
2022 (E)
Table 41: China Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 42: China Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 43: China 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 44: China Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 45: China Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 46: China 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
EUROPE
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Europe for
2022 (E)
Table 47: Europe Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR
Table 48: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 49: Europe 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
Table 50: Europe Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 51: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 52: Europe 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 53: Europe Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 54: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 55: Europe 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
FRANCE
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in France for
2022 (E)
Table 56: France Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 57: France Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 58: France 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 59: France Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 60: France Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 61: France 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
GERMANY
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Germany for
2022 (E)
Table 62: Germany Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 63: Germany Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 64: Germany 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 65: Germany Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 66: Germany Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 67: Germany 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
ITALY
Table 68: Italy Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 69: Italy Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 70: Italy 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 71: Italy Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 72: Italy Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 73: Italy 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
UNITED KINGDOM
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in the United
Kingdom for 2022 (E)
Table 74: UK Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 75: UK Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 76: UK 15-Year Perspective for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value
Sales for Targeted Therapy, Immunotherapy and Chemotherapy for
the Years 2012, 2021 & 2027
Table 77: UK Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 78: UK Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 79: UK 15-Year Perspective for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Percentage Breakdown of
Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
SPAIN
Table 80: Spain Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 81: Spain Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 82: Spain 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 83: Spain Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 84: Spain Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 85: Spain 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
RUSSIA
Table 86: Russia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 87: Russia Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 88: Russia 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2021 & 2027
Table 89: Russia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 90: Russia Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 91: Russia 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2021 & 2027
REST OF EUROPE
Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 93: Rest of Europe Historic Review for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 94: Rest of Europe 15-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage
Breakdown of Value Sales for Targeted Therapy, Immunotherapy
and Chemotherapy for the Years 2012, 2021 & 2027
Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by
Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large
Cell Carcinoma - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 96: Rest of Europe Historic Review for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 97: Rest of Europe 15-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Percentage
Breakdown of Value Sales for Adenocarcinoma, Squamous Cell
Carcinoma and Large Cell Carcinoma for the Years 2012, 2021 &
2027
ASIA-PACIFIC
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Asia-
Pacific for 2022 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 99: Asia-Pacific Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 100: Asia-Pacific 15-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Geographic Region -
Percentage Breakdown of Value Sales for Australia, India, South
Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 &
2027
Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 102: Asia-Pacific Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 103: Asia-Pacific 15-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage
Breakdown of Value Sales for Targeted Therapy, Immunotherapy
and Chemotherapy for the Years 2012, 2021 & 2027
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by
Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large
Cell Carcinoma - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 105: Asia-Pacific Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 106: Asia-Pacific 15-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Percentage
Breakdown of Value Sales for Adenocarcinoma, Squamous Cell
Carcinoma and Large Cell Carcinoma for the Years 2012, 2021 &
2027
AUSTRALIA
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Australia
for 2022 (E)
Table 107: Australia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 108: Australia Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 109: Australia 15-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage
Breakdown of Value Sales for Targeted Therapy, Immunotherapy
and Chemotherapy for the Years 2012, 2021 & 2027
Table 110: Australia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 111: Australia Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 112: Australia 15-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Percentage
Breakdown of Value Sales for Adenocarcinoma, Squamous Cell
Carcinoma and Large Cell Carcinoma for the Years 2012, 2021 &
2027
INDIA
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in India for
2022 (E)
Table 113: India Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 114: India Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 115: India 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032349/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
